Patients with locally advanced cervical cancer usually receive chemoradiotherapy (CRT) as first-line therapy, although this approach is generally not curative. Now, data from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial demonstrate that adding the anti-PD-1 antibody pembrolizumab to CRT reduces the risk of disease progression in this setting.

A total of 1,060 women with node-positive FIGO stage IB2–IIB or stage III–IVA squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix were randomly assigned (1:1) to receive CRT plus either pembrolizumab or placebo followed by maintenance pembrolizumab or placebo. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.

局部晚期宫颈癌患者通常接受放化疗（CRT）作为一线治疗，尽管这种方法通常无法治愈。现在，III 期 ENGOT-cx11/GOG-3047/KEYNOTE-A18 试验的数据表明，在 CRT 中添加抗 PD-1 抗体派姆单抗可降低这种情况下疾病进展的风险。

总共 1,060 名患有淋巴结阳性FIGO IB2–IIB 期或 III–IVA 期宫颈鳞状细胞癌、腺癌或腺鳞癌的女性被随机分配 (1:1) 接受 CRT 加派姆单抗或安慰剂，随后接受维持派姆单抗或安慰剂。无进展生存期（PFS）和总生存期（OS）是共同主要终点。